Products
HUMIRA (adalimumab injection)
PrHUMIRA® is indicated for the treatment of active moderate to severe HS in adult and adolescent patients (12 to 17 years of age weighing ≥30 kg), who have not responded to conventional therapy (including systemic antibiotics).
Consult the Product Monograph at abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/HUMIRA_PM_EN.pdf for contraindications, serious warnings and precautions, other warnings and precautions, adverse reactions, interactions, dosing, conditions of clinical use and storage and handling. The Product Monograph is also available by calling us at 1-866-848-6472.
RINVOQ (upadacitinib)
PrRINVOQ® is indicated for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe AD who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. RINVOQ can be used with or without topical corticosteroids.
Consult the Product Monograph at rinvoq.ca/pm for contraindications, serious warnings and precautions, other warnings and precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling us at 1-888-704-8271.
CA-ABBV-230036A / OC23